US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its ...
Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.03 which represents a decrease of $-1.16 or -1.36% from the prior close of $85.19. The stock opened at $85.62 and touched a low of $83 ...
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...
A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback